MX2016010791A - Inmunoterapia con multiples objetivos dirigida por biomarcadores. - Google Patents

Inmunoterapia con multiples objetivos dirigida por biomarcadores.

Info

Publication number
MX2016010791A
MX2016010791A MX2016010791A MX2016010791A MX2016010791A MX 2016010791 A MX2016010791 A MX 2016010791A MX 2016010791 A MX2016010791 A MX 2016010791A MX 2016010791 A MX2016010791 A MX 2016010791A MX 2016010791 A MX2016010791 A MX 2016010791A
Authority
MX
Mexico
Prior art keywords
biomarker
disease
subject
fusion protein
biological sample
Prior art date
Application number
MX2016010791A
Other languages
English (en)
Inventor
Petit Robert
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MX2016010791A publication Critical patent/MX2016010791A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Esta invención proporciona métodos y composiciones para su uso en la evaluación de la expresión de biomarcadores en una enfermedad y para proporcionar un enfoque inmunoterapéutico basado en Listeria con múltiples objetivos contra dicha enfermedad. En un aspecto relacionado, la invención se refiere a un método para tratar una enfermedad en un sujeto, el método comprende las etapas de: a. obtener una muestra biológica de dicho sujeto; b. evaluar la expresión de un número predeterminado de biomarcadores en dicha muestra biológica; c. administrar a dicho sujeto una composición que comprende una cepa de Listeria recombinante, dicha cepa comprende una secuencia de ácido nucleico que codifica al menos una proteína de fusión, en donde dicha proteína de fusión comprende un biomarcador identificado en dicha muestra biológica, en donde dicho biomarcador se asocia con dicha enfermedad, en donde dicho biomarcador se fusiona a un polipéptido que contiene PEST, y en donde cada proteína de fusión dentro de dicha Listeria comprende un biomarcador diferente, y de esta manera se trata dicha enfermedad en dicho sujeto.
MX2016010791A 2014-02-18 2015-02-18 Inmunoterapia con multiples objetivos dirigida por biomarcadores. MX2016010791A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461941072P 2014-02-18 2014-02-18
PCT/US2015/016348 WO2015126921A1 (en) 2014-02-18 2015-02-18 Biomarker directed multi-target immunotherapy

Publications (1)

Publication Number Publication Date
MX2016010791A true MX2016010791A (es) 2017-04-27

Family

ID=53878905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010791A MX2016010791A (es) 2014-02-18 2015-02-18 Inmunoterapia con multiples objetivos dirigida por biomarcadores.

Country Status (14)

Country Link
US (1) US10143734B2 (es)
EP (1) EP3107566A4 (es)
JP (1) JP2017511796A (es)
KR (1) KR20160130774A (es)
CN (1) CN106456726A (es)
AU (1) AU2015219161A1 (es)
BR (1) BR112016019057A2 (es)
CA (1) CA2947358A1 (es)
HK (1) HK1232139A1 (es)
IL (1) IL247300A0 (es)
MX (1) MX2016010791A (es)
RU (1) RU2016136855A (es)
SG (1) SG11201606677XA (es)
WO (1) WO2015126921A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
CA2947358A1 (en) 2014-02-18 2015-08-27 Advaxis, Inc. Biomarker directed multi-target immunotherapy
SG11201608820WA (en) 2014-04-24 2016-11-29 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
SG11201806392XA (en) * 2016-01-27 2018-08-30 Advaxis Inc Personalized delivery vector-based immunotherapy and uses thereof
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
CA3075849A1 (en) 2017-09-19 2019-03-28 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
DK0681479T3 (da) * 1993-01-29 1999-11-08 Vetrepharm Inc Immunterapeutisk præparat
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US20070264279A1 (en) 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
AU2001255196A1 (en) 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
EP1594560A4 (en) 2003-01-09 2007-06-06 Univ Pennsylvania COMPOSITIONS, METHODS AND KITS ENHANCING THE IMMUNOGENECITY OF A BACTERIAL VACCINE VECTOR
US7855064B2 (en) 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
ES2543079T3 (es) 2004-08-13 2015-08-14 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia antibiótica
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
ES2657168T3 (es) 2006-08-15 2018-03-01 The Trustees Of The University Of Pennsylvania Composiciones que comprenden HMW-MAA y fragmentos de este para el tratamiento del cáncer
WO2008130551A2 (en) 2007-04-16 2008-10-30 The Trustees Of The University Of Pennsylvania Antibiotic resistance free listeria strains and methods for constructing and using same
US9084747B2 (en) 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
EP2288379A4 (en) 2008-05-19 2012-08-08 Advaxis DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
DK2403935T3 (en) 2009-03-04 2017-09-11 Univ Pennsylvania COMPOSITIONS CONTAINING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20110305724A1 (en) 2010-04-19 2011-12-15 Yvonne Paterson Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
JP5981436B2 (ja) * 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
GB201211158D0 (en) 2012-06-22 2012-08-08 Univ Nottingham Trent Biomarkers and uses thereof
CA2947358A1 (en) 2014-02-18 2015-08-27 Advaxis, Inc. Biomarker directed multi-target immunotherapy
RU2016137834A (ru) 2014-02-25 2018-03-29 Адваксис, Инк. КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
RU2016138601A (ru) 2014-03-05 2018-04-05 Адваксис, Инк. Способы и композиции для повышения соотношения эффекторных т-клеток к регуляторным т-клеткам
SG11201608820WA (en) 2014-04-24 2016-11-29 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
EP3137107A4 (en) 2014-05-02 2018-01-17 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
CN114984228A (zh) 2014-07-18 2022-09-02 阿德瓦希斯股份有限公司 用于治疗***癌的pd-1拮抗剂和基于李斯特菌的疫苗的组合
SG11201700090RA (en) 2014-07-18 2017-02-27 Advaxis Inc Listeria-based immunogenic compositions for eliciting anti-tumor responses
WO2016011320A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Bivalent listeria-based delivery system of heterologous antigens
MX2017000838A (es) 2014-07-18 2017-09-01 Advaxis Inc Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas.
JP2016072334A (ja) 2014-09-29 2016-05-09 日本ゼオン株式会社 積層体の製造方法
KR20170068560A (ko) 2014-10-14 2017-06-19 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 암 치료에서의 병용 요법
MA41217A (fr) 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
WO2016126876A2 (en) 2015-02-03 2016-08-11 Advaxis, Inc. Listeria-based adjuvants
WO2016126878A2 (en) 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Listeria-based immunomodulation
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016154412A2 (en) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
WO2016183361A1 (en) 2015-05-13 2016-11-17 Advaxis, Inc. Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof
JP2018515588A (ja) 2015-05-26 2018-06-14 アドバクシス， インコーポレイテッド 個別化送達ベクターに基づく免疫療法とその使用
KR20180027501A (ko) 2015-06-24 2018-03-14 어드박시스, 인크. 맞춤형 전달 벡터-기반 면역 요법을 위한 제조 장치 및 공정
US20180305702A1 (en) 2015-09-15 2018-10-25 Advaxis, Inc. Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment
MA42841A (fr) 2015-09-15 2018-07-25 Advaxis Inc Procédé de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria de recombinaison
JP2018527382A (ja) 2015-09-17 2018-09-20 アドバクシス， インコーポレイテッド 組み換え型リステリアワクチン株および癌免疫療法におけるその使用方法
TW201722444A (zh) 2015-10-14 2017-07-01 艾***公司 重組李斯特菌疫苗菌株及在癌症免疫治療中使用該菌株之方法
WO2017085691A1 (en) 2015-11-20 2017-05-26 Advaxis, Inc. Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strain
US20180360940A1 (en) 2015-12-16 2018-12-20 Advaxis, Inc. Listeria-based immunotherapy and methods of use thereof
SG11201806392XA (en) 2016-01-27 2018-08-30 Advaxis Inc Personalized delivery vector-based immunotherapy and uses thereof
WO2018009461A1 (en) 2016-07-05 2018-01-11 Advaxis, Inc. Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof

Also Published As

Publication number Publication date
HK1232139A1 (zh) 2018-01-05
CA2947358A1 (en) 2015-08-27
SG11201606677XA (en) 2016-09-29
US20170106072A1 (en) 2017-04-20
EP3107566A4 (en) 2017-10-11
JP2017511796A (ja) 2017-04-27
RU2016136855A (ru) 2018-03-22
CN106456726A (zh) 2017-02-22
IL247300A0 (en) 2016-09-29
EP3107566A1 (en) 2016-12-28
BR112016019057A2 (pt) 2017-10-10
AU2015219161A1 (en) 2016-09-29
US10143734B2 (en) 2018-12-04
WO2015126921A1 (en) 2015-08-27
KR20160130774A (ko) 2016-11-14

Similar Documents

Publication Publication Date Title
MX2016010791A (es) Inmunoterapia con multiples objetivos dirigida por biomarcadores.
MX2021011696A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
MX2017011406A (es) Terapeuticos de anticuerpo que se unen a tim3.
MX2019006340A (es) Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
BR112018010385A2 (pt) anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer.
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
SG10201808565QA (en) Fgfr fusions
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
BR112017009262A2 (pt) métodos de produção de proteínas de duas cadeias em bactérias
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
PH12017500309A1 (en) Anti-vasa antibodies, and methods of production and use thereof
NZ760789A (en) Uti fusion proteins
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
EA201692495A8 (ru) Биспецифические антитела к il4-il13
MX2018003445A (es) Expresion de proteinas que contienen fc.
AR100427A1 (es) PROTEÍNAS DE UNIÓN A ANTÍGENO DE HER1 QUE SE UNEN A LA HORQUILLA b DE HER1
ZA202001389B (en) Non-human animals expressing humanized c1q complex
MX2016001678A (es) Construcciones de expresion y metodos para expresar polipeptidos en celulas eucariotas.
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
EA201892124A1 (ru) Днк-конструкции антител и способы их применения